Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
Viatris, Inc. (VTRS), Opus Genetics, Inc. (IRD) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The study, officially titled “Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions,” tested an eye drop for night vision issues after laser vision correction. It aims to address a real unmet need for people who struggle with glare and low-light vision, which could open a new niche in the eye-care market.
The main treatment is a daily eye drop called 0.75% phentolamine ophthalmic solution, also known as Nyxol. It is designed to improve low-light and night vision for patients who have visual disturbances after refractive surgery, while a placebo drop is used as a comparison.
The study used a randomized design, which means participants were put into treatment or placebo groups by chance. It was also double-masked with multiple parties blinded, so patients, doctors, and study staff did not know who received the active drug, helping to reduce bias and make the results more reliable for future regulatory review.
This was an interventional trial with parallel groups, meaning both treatment arms ran at the same time. The primary purpose was treatment, focusing on whether the drops improve vision quality in low light, an outcome that could support labeling expansion and broader clinical use if the results are strong.
The trial is listed as Phase 3, signaling it is in a late stage of testing before potential wider approval. For investors, this stage often marks a key risk-reward point, because positive data from such a phase can drive partnerships, regulatory filings, or commercialization steps.
The study was first submitted on April 1, 2024, which marked the formal start of public tracking on ClinicalTrials. The most recent update was filed on March 10, 2026, signaling that the sponsor has refreshed information and that the record reflects current status.
The overall status is now listed as completed, meaning patient treatment and follow-up are finished. The absence of posted results so far keeps the market in a wait-and-see mode, and investors will likely watch closely for any top-line data release or conference presentations.
For Viatris Inc. (VTRS), a positive outcome could support a new revenue stream in specialty eye care and slightly improve the company’s growth profile. While Viatris is large and diversified, even a modestly successful niche product can improve sentiment if it demonstrates strategic execution in higher-margin branded assets.
Ocuphire Pharma, Inc., the lead sponsor, has more concentrated exposure to the outcome, so the trial result could move its valuation more sharply than Viatris. Success could also make Ocuphire a more attractive partner or acquisition target for larger ophthalmology or specialty pharma players.
For Opus Genetics, Inc. (IRD), which focuses on inherited retinal diseases, this update is indirectly relevant because it underscores ongoing innovation in eye-care pipelines that investors track together. Strong data across late-stage eye programs often supports broader confidence in the ophthalmology space, though direct read-through to Opus is limited.
Competitors in night vision and refractive surgery complication management are still limited, so first-mover advantage could be meaningful for Nyxol if approved. However, generic pressure and payer scrutiny in the U.S. will likely keep pricing and adoption under close watch, which investors should factor into any revenue models.
Overall, the completion of this Phase 3 trial reduces development risk, but the main stock driver will be the eventual release and quality of the efficacy and safety data. Until those results are public, market reaction for Viatris and related names is likely to be muted, with only modest speculative positioning around potential upside.
The study record for 0.75% phentolamine ophthalmic solution has been recently updated and is now listed as completed, with further details available on the ClinicalTrials portal.
To learn more about VTRS’s potential, visit the Viatris, Inc. drug pipeline page.
